Search Results

Bluejay Diagnostics, Inc. today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-8 (the “Reverse Stock Split”).

Bluejay Diagnostics, Inc. announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

Bluejay Diagnostics, Inc. today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

Bluejay Diagnostics, Inc. reported its financial results for the quarter and nine months ended September 30, 2023.

Bluejay Diagnostics, Inc., announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients.

Exicure, Inc., (NASDAQ:XCUR) and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. (“Bluejay”) and Exicure, Inc. (“Exicure”) entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.

Bluejay Diagnostics, Inc. announced the pricing of a public offering of 2,692,308 shares of the Company’s common stock and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share and associated warrant.

Bluejay Diagnostics, Inc. announced the closing of its previously announced public offering of 2,692,308 shares of the Company’s common stock and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share and associated warrant.

Bluejay Therapeutics, a leader in the development of novel therapeutics, announced the successful closure of a $182 million Series C financing round.

Bluejay Therapeutics announced that the European Medicines Agency has issued a positive opinion on the Company’s application for orphan designation for BJT-778 for the treatment of chronic hepatitis D.